Patient with Asthma Suffering from Treatment-Related Conjunctivitis: Clinical Consults

Activity Overview

We thank our learners for submitting their difficult asthma cases! Our faculty have reviewed the submissions and have come together to discuss assessment/management strategies for the selected case. Tune in to find out what our pulmonologists and allergist/immunologist have to say.

0.25 CE Credit(s)
Expires: February 27, 2021

Target Audience

The target audience for this activity is US-based pulmonologists, allergists, and immunologists, as well as NPs and PAs who diagnosis and manage difficult-to-treat and severe asthma.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Identify patients with poorly-controlled or difficult-to-treat asthma who are eligible for step-up therapies, including new and emerging biologics
  • Incorporate new and emerging targeted biologics into the management of patients with severe or poorly-controlled asthma, when appropriate

Activity Faculty

Reynold A. Panettieri, Jr, MD

Reynold Panettieri, MD

Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
Emeritus Professor, Medicine
New Brunswick, NJ

Michael E. Wechsler, MD, MMSc

Michael E. Wechsler, MD, MMSc

Co-Director, The Cohen Family Asthma Institute
Professor, Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Jonathan Corren, MD

Jonathan Corren, MD

Clinical Associate Professor, Medicine and Pediatrics Division of Clinical Immunology and Allergy
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA